使用Player FM应用程序离线!
Expert Thoughts on Key Trials of Interest for Ovarian and Cervical Cancer at the IGCS 2022 Annual Global Meeting
Manage episode 345141698 series 3256997
In this episode,Susana Banerjee, MBBS, MA, PhD, and Mansoor Raza Mirza, MD, share their thoughts on key studies of interested presented at the IGCS 2022 Annual Global Meeting for ovarian and cervical cancers including:
- Post-hoc analyses from SOLO-3: olaparib vs physician’s choice chemotherapy in germline BRCA mutant platinum-sensitive recurrent ovarian cancer
- Phase III CALLA trial: durvalumab combined with and following chemoradiation for locally-advanced cervical cancer
- Phase III ARIEL3: final OS for maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent high-grade serous ovarian cancer
- Retrospective NeCTuR study: outcomes with topotecan, paclitaxel, and bevacizumab (TPB) vs non-TPB regimens for recurrent high-grade neuroendocrine carcinoma of the cervix
Presenters:
Susana Banerjee, MBBS, MA, PhD, FRCP
Consultant Medical Oncologist and Research Lead
Gynaecology Unit
Royal Marsden NHS Foundation Trust
London, United Kingdom
Mansoor Raza Mirza, MD
Chief Oncologist
Department of Oncology
Rigshopitalet – Copenhagen University Hospital
Copenhagen, Denmark
Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.
Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/38xuRBv
168集单集
Manage episode 345141698 series 3256997
In this episode,Susana Banerjee, MBBS, MA, PhD, and Mansoor Raza Mirza, MD, share their thoughts on key studies of interested presented at the IGCS 2022 Annual Global Meeting for ovarian and cervical cancers including:
- Post-hoc analyses from SOLO-3: olaparib vs physician’s choice chemotherapy in germline BRCA mutant platinum-sensitive recurrent ovarian cancer
- Phase III CALLA trial: durvalumab combined with and following chemoradiation for locally-advanced cervical cancer
- Phase III ARIEL3: final OS for maintenance rucaparib vs placebo following response to platinum-based chemotherapy for recurrent high-grade serous ovarian cancer
- Retrospective NeCTuR study: outcomes with topotecan, paclitaxel, and bevacizumab (TPB) vs non-TPB regimens for recurrent high-grade neuroendocrine carcinoma of the cervix
Presenters:
Susana Banerjee, MBBS, MA, PhD, FRCP
Consultant Medical Oncologist and Research Lead
Gynaecology Unit
Royal Marsden NHS Foundation Trust
London, United Kingdom
Mansoor Raza Mirza, MD
Chief Oncologist
Department of Oncology
Rigshopitalet – Copenhagen University Hospital
Copenhagen, Denmark
Content supported by educational grants from AstraZeneca, GlaxoSmithKline, Karyopharm Therapeutics, and Merck Sharp & Dohme Corp.
Link to full program, including a downloadable highlights slideset, and ClinicalThought commentaries:
https://bit.ly/38xuRBv
168集单集
所有剧集
×欢迎使用Player FM
Player FM正在网上搜索高质量的播客,以便您现在享受。它是最好的播客应用程序,适用于安卓、iPhone和网络。注册以跨设备同步订阅。